You are here: Industry Insights > Sobi

News List

AZ sells rights to RSV virus drug to Sobi for $1.5bn pharmaphorum
December 11, 2018
AstraZeneca has agreed to sell the rights to its drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for an upfront $1.5 billion in cash and shares, plus certain conditional payments.
US OKs first treatment for haemophagocytic lymphohistiocytos pharmatimes
November 22, 2018
US regulators have approved Swedish Orphan Biovitrum (Sobi) and Novimmune’s Gamifant as the first treatment for the rare disorder primary haemophagocytic lymphohistiocytosis.
Sobi to buy US rights to AstraZeneca’s Synagis drug for $1.5bn pharmaceutical-technology
November 15, 2018
Swedish biopharmaceutical firm Swedish Orphan Biovitrum (Sobi) has signed agreements to acquire the rights to AstraZeneca’s Synagis (palivizumab) medicine in the US for an upfront payment of $1.5bn.
AstraZeneca to Divest US Synagis Rights to Sobi americanpharmaceuticalreview
November 14, 2018
AstraZeneca to Divest US Synagis Rights to Sobi
AstraZeneca sells off paediatric lung infection drug to Sobi for $1.5bn pharmatimes
November 14, 2018
AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to respiratory syncytial virus (RSV)...
Sobi launches Kineret for AOSD, SJIA pharmatimes
July 17, 2018
Sobi UK and Ireland has announced the launch of Kineret across the country offering a new treatment option for Adult Onset Stills Disease (AOSD) and Systemic-Onset Juvenile Idiopathic Arthritis (SJIA).
Sobi Receives Approval from Health Canada for Once-Daily Dosing of Orfadin® (nitisinone) for the Treatment of HT-1 biospace
April 18, 2018
Sobi, a pioneering international biopharmaceutical company dedicated to rare diseases, has received approval from Health Canada for a reduced dosing frequency for Orfadin® (nitisinone).
Sobi Receives IND Acceptance from FDA contractpharma
January 24, 2018
Swedish Orphan Biovitrum (Sobi) has announced that the FDA has accepted their investigational new drug (IND) application for the drug candidate SOBI003. In addition, SOBI003 was granted Fast Track status by the FDA.
Sweden’s Sobi debates sale of Partner Products business area pharmaceutical-technology
February 07, 2017
Swedish Orphan Biovitrum (Sobi) has confirmed that the company is holding discussions with a private equity firm regarding a possible sale of its Partner Products business area.

Previous page 1 2 Next page